Latest major adult hypertension treatment guidelines
1. United States: 2025 AHA/ACC Multisociety Guideline
This is the newest major US guideline, published August 2025, replacing the 2017 ACC/AHA guideline. See the official
AHA guideline overview and
key recommendations.
BP categories
- Stage 1: 130-139 systolic or 80-89 diastolic
- Stage 2: ≥140 systolic or ≥90 diastolic
When to start medication
- Start medication for confirmed average BP ≥140/90 mmHg.
- Start at ≥130/80 mmHg if there is cardiovascular disease, prior stroke, diabetes, chronic kidney disease, or 10-year CVD risk ≥7.5%.
- For lower-risk people at 130-139/80-89, begin medication if BP remains high after 3-6 months of lifestyle treatment.
BP target
- Generally <130/80 mmHg for adults, individualized for frailty, limited life expectancy, pregnancy, and clinical circumstances.
First-line drugs
- Thiazide or thiazide-like diuretic, such as chlorthalidone or indapamide
- ACE inhibitor
- ARB
- Long-acting dihydropyridine calcium-channel blocker, such as amlodipine
Stage 2 hypertension
- Start two first-line drugs from different classes, preferably as a fixed-dose single-pill combination.
For the BP previously described, 150/100 mmHg, this qualifies as stage 2 hypertension if confirmed by correct repeat and home readings. The guideline supports clinician-directed treatment with two first-line agents, not routine furosemide alone. Choice depends on kidney function, potassium, diabetes/albuminuria, heart failure, pregnancy potential, edema, and concurrent medicines.
2. Europe: 2024 ESC Guideline
The latest ESC guideline is the
2024 ESC hypertension guideline. It emphasizes accurate office and home/ambulatory BP measurement, overall cardiovascular risk, lifestyle treatment, and individualized medication. The
ESC guideline hub provides supporting resources.
3. Global reference: WHO 2021 Guideline
The latest WHO pharmacologic guideline remains its 2021 document. It recommends three first-line categories: thiazide/thiazide-like diuretics, ACE inhibitor or ARB, and long-acting dihydropyridine calcium-channel blocker. It also supports initial combination therapy, ideally a single-pill combination, when drug treatment is needed. See the
WHO guideline.
Safety points
- Do not combine an ACE inhibitor and an ARB.
- Avoid ACE inhibitors and ARBs during pregnancy or if pregnancy is possible without specialist guidance.
- Check creatinine/eGFR and potassium before and after starting or increasing an ACE inhibitor, ARB, or diuretic.
- Furosemide is mainly for fluid overload, heart failure, or particular kidney-related indications, not standard first-line management of uncomplicated hypertension.
- BP >180/120 with chest pain, shortness of breath, neurologic symptoms, confusion, vision changes, or severe new headache requires emergency assessment.
Recent guideline evidence also includes the 2025 Canadian primary-care guideline, Goupil et al., CMAJ [PMID: 40419299], and the 2024 European Society of Hypertension guideline, Kreutz et al., European Journal of Internal Medicine [PMID: 38914505].